Amoun Pharmaceutical

What Amoun Pharmaceutical does

Amoun Pharmaceutical Company S.A.E. is one of Egypt's largest branded pharmaceutical manufacturers, producing and exporting human medicines across antibiotics, gastrointestinal, neurological, and anti-inflammatory therapeutic categories. The company operates a state-of-the-art manufacturing facility in El Obour City designed by John Brown Co., producing diverse dosage forms including film-coated and orally disintegrating tablets, hard and soft gelatin capsules, effervescent powders, oral liquids, sterile ampoules and vials, B-lactam formulations, and topical creams and gels. Founded in 1998 by Dr. Tharwat Bassily and headquartered in Qalyubia, Egypt, Amoun generated EGP 5.7 billion in 2023 sales, representing an 18% five-year CAGR, with a 4.82% share of Egypt's pharmaceutical market by value and 9.31% by prescription volume.

The company runs a sales-led go-to-market model anchored by a 680-person sales and marketing team that conducts cycle meetings, seminars, workshops, and product launches with healthcare professionals across Egypt, supported by five domestic commercial offices in Cairo, Mansoura, Assiut, Alexandria, and Minya. An export group distributes over 230 registered products to 29+ countries across the Middle East, Africa, Asia, and Eastern Europe, with a Dubai Healthcare City office anchoring international operations. The business model is B2B and B2C pharmaceutical sales with quote-based institutional pricing; no public pricing is disclosed. Amoun operates an e-commerce-enabled corporate website on Odoo infrastructure, maintains ISO 45001 and ISO 50001 certifications, and complies with GMP, EDA, and WHO guidelines.

Following its 2021 acquisition by Abu Dhabi Developmental Holding Company (ADQ), Amoun became part of the Arcera life sciences holding company, which in April 2024 consolidated Amoun with Swiss-based Acino and Turkey-based Birgi Mefar Group into a unified platform of over 2,000 branded medicines and 6,500+ employees. The December 2024 'One Arcera – One Team, One Purpose' restructuring, effective 1 January 2025, organized Arcera into two units — Arcera Branded Generics and Arcera Technical Operations — led by CEO Isabel Afonso from Abu Dhabi. As part of Arcera, Amoun functions as the MENA manufacturing and commercial anchor under Chairman Mohamed Heshmat, with the broader platform positioned as a global life sciences vehicle aligned with Abu Dhabi's economic diversification strategy.

Name

Amoun Pharmaceutical

Legal name

Amoun Pharmaceutical Company S.A.E.

Website

https://amoun.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Amoun Pharmaceutical is Egypt's leading branded generic drug manufacturer, producing antibiotics, gastrointestinal, neurological, and anti-inflammatory medicines from a large-scale El Obour City facility and exporting to 29+ countries, now operating as the MENA anchor within ADQ's Arcera life sciences platform.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Specialty Pharmaceutical Distributors (HLAIAJAB), Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

Keywords

• Branded pharmaceutical manufacturing
• Human pharmaceuticals
• Pharmaceutical dosage forms
• Generic medicines
• Pharmaceutical exports

Headquarters

HQ city

Cairo

HQ country

Egypt

HQ region

Africa

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Amoun generates revenue through the development, manufacturing, marketing, distribution, and export of branded pharmaceutical products. The company achieved sales of EGP 5.7 billion in 2023 with an 18% CAGR over five years.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Amoun develops, manufactures, markets, distributes, and exports branded human pharmaceutical products across multiple therapeutic segments including antibiotics, gastrointestinal, neurological, and anti-inflammatory categories. The company operates one of Africa and the Middle East's largest pharmaceutical manufacturing facilities, producing diverse dosage forms such as tablets, capsules, sterile ampoules and vials, effervescent granules, oral liquids, creams, gels, and β-lactam products for the Egyptian domestic market and export to over 29 countries.

Product overview

Amoun Pharmaceutical is a branded pharmaceutical manufacturer offering a broad portfolio of human pharmaceutical products spanning multiple therapeutic areas including antibiotics (Hibiotic, Xithrone), anti-inflammatory (Alphintern), gastrointestinal (Antodine, Antinal), and neurological (Neuroton) segments. The company operates as part of Arcera under ADQ, structured into two primary units: Arcera Branded Generics (consolidating Amoun's commercial sales and marketing operations) and Arcera Technical Operations (encompassing Amoun's manufacturing, quality, R&D, and supply chain). Amoun's manufacturing facility in El Obour City is one of the largest in Africa and the Middle East, producing solid dosage forms (tablets, capsules), effervescent and powder forms, liquids and semi-solids (syrups, drops, sprays), sterile forms (ampoules, vials), B-lactam antibiotics, and topical formulations (creams, gels, ointments). The company distributes branded pharmaceutical products across Egypt and exports to over 29 countries.

Differentiator

Problem solved

Functional benefit

Brands

• One Arcera: Unified organizational structure launched in December 2024 integrating Amoun with Acino and Birgi Mefar Group under Arcera life sciences platform.

Products and services

• Hibiotic Tablets & Suspension Branded antibiotic pharmaceutical product available in tablet and oral suspension dosage forms for the Egyptian and export markets.
• Alphintern Tablets Branded anti-inflammatory enzyme preparation available in tablet form.
• Xithrone Tablets & Suspension Branded antibiotic pharmaceutical product available in tablet and oral suspension dosage forms.
• Antodine Tablets & Ampoules Branded gastrointestinal pharmaceutical product available in tablet and sterile injectable ampoule forms.
• Antinal Capsules & Suspension Branded gastrointestinal pharmaceutical product available in capsule and oral suspension forms.
• Neuroton Tablets & Ampoules Branded neurological pharmaceutical product available in tablet and sterile injectable ampoule forms.
• Registered Pharmaceutical Products Portfolio Portfolio of over 230 registered branded pharmaceutical products distributed across GCC countries, Africa, Asia, and Eastern Europe.
• Pharmaceutical Contract Manufacturing Services Large-scale GMP-compliant contract manufacturing of diverse dosage forms for multinational pharmaceutical innovators and partners in the Middle East and Africa region.

Quantifiable outcome

• 4.82% market share in Egyptian pharmaceutical market (2023 IQVIA data)
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and minor.

• AcinocoreStrategic or Co-development PartnerAcino is one of the three consolidated entities under Arcera holding company, alongside Amoun and Birgi Mefar Group. Together they offer more than 2000 branded medicines across a wide range of therapeutic areas, supported by a combined workforce of over 6500 people.
• Birgi Mefar GroupcoreStrategic or Co-development PartnerBirgi Mefar Group is one of the three consolidated entities under Arcera holding company. The consolidation creates a global life sciences company with diversified manufacturing and commercial operations across multiple regions.
• Multinational Pharmaceutical PartnersminorStrategic or Co-development PartnerAmoun maintains manufacturing partnerships with multinational pharmaceutical companies, serving as a trusted manufacturing partner for innovators and multinationals seeking production capabilities in the Middle East and Africa region.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• EIPICO (Egyptian International Pharmaceutical Industries Company): One of the largest Egyptian pharmaceutical manufacturers producing branded generics across a broad therapeutic portfolio. Directly comparable as a domestic peer competing for the same physicians, pharmacies, and tender business in Egypt.
• Eva Pharma: Leading Egyptian pharmaceutical manufacturer with broad branded generic portfolio and significant export footprint in MENA and Africa. Closely comparable in scale, therapeutic breadth, and go-to-market model targeting Egyptian physicians and export partners.
• Pharco Pharmaceuticals: One of the largest privately held Egyptian pharma companies, producing branded generics and OTC products with strong regional presence. Comparable as a domestic competitor in similar therapeutic categories and the same hospital/pharmacy channels.
• Acino: Swiss-headquartered branded generics player now consolidated alongside Amoun under ADQ's Arcera platform. Comparable as a sister entity within Arcera Branded Generics, sharing therapeutic categories and a similar go-to-market through local partners.
• Birgi Mefar Group: Turkish pharmaceutical manufacturer serving as Amoun's third sister company within Arcera Technical Operations. Comparable in dosage form capabilities, contract manufacturing services, and emerging-markets orientation.

Regional players

• Julphar (Gulf Pharmaceutical Industries): UAE-based branded generics manufacturer with MENA distribution footprint. Comparable as a regional pharma manufacturer operating across similar therapeutic categories and serving GCC/African markets that overlap with Amoun's export geography.
• SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation): Saudi-listed pharmaceutical manufacturer producing branded generics across multiple therapeutic areas for the Saudi and wider MENA market. Comparable in therapeutic breadth, branded-generic positioning, and GCC-focused commercial approach.

Broad incumbents

• Hikma Pharmaceuticals: Jordan-headquartered multinational pharmaceutical company with broad branded generics and injectables portfolio across MENA and the US. Comparable as a larger incumbent operating in the same therapeutic categories and regional channels as Amoun.
• Aspen Pharmacare: South Africa's largest pharmaceutical manufacturer with a broad branded generics portfolio across Africa and emerging markets. Comparable as a scaled African pharma platform competing for similar tender and private-channel business in Sub-Saharan Africa.
• Cipla: Indian multinational with one of the largest emerging-market branded generics footprints, including Africa. Comparable in therapeutic breadth, dosage form diversity, and emerging-market commercial model that intersects with Amoun's export ambitions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/102393
• LinkedInlinkedin.com/company/amoun-pharmaceutical-industries-company
• Xx.com/AmounPharmaceut
• YouTubeamoun.com/website/social/youtube
• Instagramamoun.com/website/social/instagram

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amoun Pharmaceutical